SkyePharma Pages on BioPortfolio:

Biotechnology News Skyepharma Search
SkyePharma finalises bonds agreement that secures its future SkyePharma has confirmed the ... Skyepharma PLC: Skyepharma - Statement re Convertible Bonds
...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=s...

SkyePharma: hope worth sharing?
Shares in SkyePharma have plunged since the company announced a ... Skyepharma originally intended to secure funding by licensing Flutiform, but considered ...
http://www.bioportfolio.com/biotech_news/datamonitor_3.htm...

BioPortfolio - Science Center Drive San Diego California 92121 U.S.A
13th January, 2004, SkyePharma Inc., 10450 Science Center Drive, San Diego, CA 92121, USA. ... http://www.bioportfolio.com/biocorporate/9587-SkyePharma.htm.
...
http://www.bioportfolio.com/search/Science_Center_Drive_San_...

BioPortfolio - skyepharma
Mintz Levin Advises SkyePharma PLC in Refinancing of Convertible Bonds . ... Shares in SkyePharma have plunged since the company announced a . ...
http://www.bioportfolio.com/search/skyepharma.html...

BioPortfolio - www.skyepharma.com
www.skyepharma.com - BioPortfolio. ... Recent Search Terms used to find this page: www.skyepharma.com | SkyePharma AB | skyepharma | skyepharma sweden . ...
http://www.bioportfolio.com/search/www.skyepharma.com.html...

BioPortfolio - skyepharma sweden
skyepharma sweden - BioPortfolio. ... SkyePharma AB, Malmö, Sweden. A novel method was developed for studying the diffusion of proteins through poly(D ..
...
http://www.bioportfolio.com/search/skyepharma_sweden.html...

BioPortfolio - SkyePharma USA
SkyePharma USA - BioPortfolio. ... Mintz Levin Advises SkyePharma PLC in Refinancing of Convertible Bonds .... USA Voicemail and Fax: (+1) 415 680 2472.
...
http://www.bioportfolio.com/search/SkyePharma_USA.html...

BioPortfolio - Press release SkyePharma 2002
Press release SkyePharma 2002 - BioPortfolio. ... SkyePharma: hope worth sharing ? Pharma companies in R&D battle as warfarin goes on . ...
http://www.bioportfolio.com/search/Press_release__SkyePharma...

Results from other life science and pharmaceutical sites:

BioSpace - Skyepharma PLC News, Search Jobs, Events
Company Profile. SkyePharma PLC 105 Piccadilly London W1J 7NJ United Kingdom Phone: 44-207-491-1777 Fax: 44-207-491-3338 SEARCH JOBS. Industry ...
http://www.biospace.com/company_profile.aspx?CompanyId=2927...

BioSpace - SkyePharma Inc. News, Search Jobs, Events
SkyePharma Inc. (SKYE) Update on Convertible Bonds and Current Trading 7/8/2008 12:04:06 PM More... GlaxoSmithKline (GSK) and SkyePharma Inc. (SKYE) Gain on ...
http://www.biospace.com/company_profile.aspx?CompanyId=69204...

SkyePharma Reacquires European Rights for DepoBupivacaine(TM)
SkyePharma will also obtain rights to the clinical data from the Phase II trials of DepoBupivacaine(TM). This is expected to simplify the ongoing divestment ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...

SkyePharma Inc. Announces CEO Succession Plan - News, Search Jobs ...
LONDON, UK, 21 May 2008 - At its Annual General Meeting later today, SkyePharma PLC (LSE:SKP.L - News) will announce that its Chief Executive Officer, ...
http://www.biospace.com/news_story.aspx?NewsEntityId=97357...

NDA 21-005 SkyePharma Inc. Attention: Gordon L. Schooley, Ph.D.
SkyePharma Inc. Attention: Gordon L. Schooley, Ph.D. Senior Vice President, Clinical Research & Regulatory Affairs. 10450 Science Center Drive ...
http://www.fda.gov/cder/foi/appletter/2000/21005ltr.pdf...

GlaxoSmithKline and SkyePharma Inc. Gain on Requip XL Drug ...
16 Jun 2008 ... The new Requip® XL(TM) formulation uses SkyePharma's patented Geomatrix(TM) technology. This innovative tri-layer formulation allows for ...
http://www.biospace.com/news_story.aspx?NewsEntityId=100275...

King Pharmaceuticals and Skyepharma Announce Licensing Agreement ...
SkyePharma's Geomatrix(R) range of technologies involves a fully- developed, multi-layered tablet technology that controls the release of a product's active
...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...

Skyepharma PLC Phase 3 FlutiformTM Study Meets Primary Endpoints ...
Ken Cunningham, COO and CEO-designate of SkyePharma, said: "This is the third of the core clinical efficacy trials to meet its primary endpoints. ...
http://www.biospace.com/news_story.aspx?NewsEntityId=102296...

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright 1997-2008 - BioPortfolio Limited.